tirzepatide updates once weekly for the treatment of obesity journal club Maintenance Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 FDA Says Shortage of GLP-1

[DOI] [PubMed] [Google Scholar] 35.Diomede F., Zini N., Gatta V., Fulle S., Merciaro I., DAurora M., La Rovere R.M., Traini T., Pizzicannella J., Ballerini P., et al

Flexible Treatment Packages Weight-loss programs often bundle: Consultation Medication Follow-up visits which reduces month-to-month cost fluctuations

Can we give them the dose every other week? Mitchell says

Among the articles presented in this study, one of the major conclusions is that there is always a degree of uncertainty, especially among the patients currently using GLP-1 RAs

Differences across outcome subgroups Out of 47,294 reports, 4,652 reports led to 5,136 serious outcomes, classified into categories including death, life-threatening, hospitalization-initial or prolonged, disability, congenital anomaly, required intervention to prevent permanent impairment/damage, and other serious. Other serious was the most common outcome, accounting for 53% of the serious cases